To transform human health.
To lead the industry in the delivery of high-value research and multi-centre randomized controlled trials that assess critical human health issues.
Robarts Clinical Trials is a niche GI Contract Research Organization. We are a wholly owned subsidiary of Western University. We have been providing a complete range of clinical research services to a broad base of academic and industry clients since 1986.
We are global. With headquarters in Canada (London, Ontario) and offices in the United States (La Jolla, California) and Europe (Amsterdam, The Netherlands), we are an international and culturally diverse organization.
We are collaborators. Robarts Clinical Trials works with pharmaceutical and biotechnology companies, government agencies, key opinion leaders and the investigator community to advance the development of effective treatments. We work alongside our clients to provide tailored and innovative recommendations for the design and implementation of their research. We work with you from concept to completion.
We are pioneers. RCT is committed to developing new solutions to improve clinical trial outcomes and accelerate drug development timelines. We were the first to bring solutions for central imaging of endoscopy and histopathology to the market and have recently built a translational science network which can accelerate and enhance early drug development.
We are evidence-based experts. Our foundation is built on expertise in inflammatory bowel disease (IBD) and clinical trial design. We are recognized as international leaders in outcomes development, cluster randomization trials, and centralized imaging solutions. Our vast R & D and clinical research experience forms the basis for our integrated solutions to complex operational needs and regulatory standards.
Content coming ...
Geert D’Haens graduated from medical school at the Katholieke Universiteirt Leuven, Belgium in 1987.
Professor D’Haens specialized in gastroenterology at the University of Chicago Hospitals, USA and University Hospitals Leuven in 1990-1992. He was board certified in internal medicine in 1992. He defended his Doctoral Thesis in 1996. Currently Professor of Medicine and Gastroenterology at the Academic Medical Centre, University of Amsterdam, Netherlands, Professor D’Haens is a specialist gastroenterologist with a clinical interest in inflammatory bowel disease and gastrointestinal oncology. He has particular expertise in mucosal immunology, gastrointestinal endoscopy and immunosuppression related to IBD.
Professor D’Haens was elected to the International Organization for Inflammatory Bowel Disease (IOIBD) in 2003 and is currently Chairman of the organization. In 1999, D'Haens was co-founder of the European Crohn's and Colitis organization ECCO.
Memberships of other societies includes a Fellowship of the American Gastroenterological Association (2006) and the European Society for Gastrointestinal Endoscopy Research Committee.
Professor D’Haens is the recipient of several awards including the Silver medal for “inflammatory bowel disease" from World Congress on Gastroenterology, Vienna, 1998.
With over 250 peer reviewed scientific articles and 37 chapters in medical textbooks Professor D’Haens has an impressive publication record and is widely recognized as an expert in the area of digestive diseases.
William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.
He completed a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. In 2016 he also became Vice Chair of Clinical Operations for the Department of Medicine and a member of the Clinical Practice Organization (CPO) Board which oversees all of UC San Diego Health System clinical practice. Dr. Sandborn has published over 599 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to Inflammatory Bowel Disease. He is currently Chief of the Division of Gastroenterology, Vice Chairman of Medicine for Clinical Operations, a member of the CPO Board, and Director of UCSD IBD Center in the UC San Diego Health System.
Leadership at Robarts Clinical Trials epitomizes business integrity, collaboration and corporate responsibility. Their collective medical, operational and business expertise works seamlessly to provide quality solutions, timely execution and fiscal attentiveness to each and every project.
Lisa Harrison joined Robarts Clinical Trials in 2013 to head up our Corporate Operations. Lisa is an organizational strategist and operational leader who has been focused on the professional services, health care and technology sectors for over 25 years.
Lisa has worked for and consulted with fast growing and high change organizations to help them align and organize their operations and structure to support their strategies and objectives. The goal has been to ensure these companies are ready for that next stage of growth. Previously, Lisa served as Chief Operating Officer (COO) for a mid-sized, international technology importer/exporter, as VP, Delivery Partner and VP of Organizational Development at an IT solutions company servicing Fortune 100 companies, as Chief Operating Officer for an international research and consulting firm, as Regional Operations Director and Director of Employee Development for an IBM Company and as Regional Director of a Canadian medical rehabilitation company.
Lisa earned her Bachelor of Arts Degree (Business) from Western University, a certificate of Health Care Administration from Fanshawe College, advanced certificates in Alternative Dispute Resolution from the University of Windsor, and her certification in Advanced Strategic HR Management from the Rotman School of Business.
Dr. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada.
His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and European Crohn’s and Colitis Organization (ECCO). He has authored over 300 articles and book chapters and has given over 90 invited presentations at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario. His research efforts focus on the design and implementation of randomized controlled trials of therapy for Inflammatory Bowel Disease. He has been the principal investigator on numerous large-scale randomized clinical trials.
Jeff Smith is the CEO (Chief Executive Officer) and Vice President, Clinical Operations at Robarts Clinical Trials.
Jeff has a clinical operations background spanning 20 years in the pharma and CRO industry. He has a strong record of leading high performing global teams that support the growth of global business units. During his time in the CRO industry he has gained exposure insights into the operations of various CRO models including government, private, public and venture capital ownership. Prior to his current positions he held senior positions including Senior Director General Medicine & Vaccines/Infectious Disease, Inventiv Health and Director, Business Development and Director, Clinical Operations, Robarts Clinical Trials. Jeff trained as a registered nurse and holds a Bachelor Degree in Health Sciences (nursing).
Tom oversees the finance team at Robarts Clinical Trials, providing direction and leadership for the financial well-being of the organization.
Since 2001, he has held various senior financial roles in the Contract Research Organization (CRO) industry, working with Inventiv Health for over 10 years before joining Robarts Clinical Trials. These experiences were invaluable and fostered a thorough understanding of the professional services business model within numerous ownership environments (government, private, public and private equity). Tom has a proven track record of managing budgets and forecasts at both project and corporate levels, as well as extensive experience in treasury, and tax compliance. Tom has an Honours Degree in Business from Wilfrid Laurier University and is a Certified General Accountant (CGA).
Terilynn Koster, Director, Data Sciences has 30 years of experience in data management, statistical programming and analysis in regulated environments including the Food and Drug Administration (FDA) and European Medicines Agency (EMA).
Prior to joining Robarts Clinical Trials, Terilynn has an extensive background of 17 years with inVentiv Health Clinical where she served as Vice President, Global Data Management where she lead over 300 people and 200 projects across 5 global data centres. Prior to joining inVentiv, Terilynn held positions with Covance and a Biostatistical Consulting group. In the past she has been an advisory board member of the Clinical Data Interchange Standards Consortium (CDISC), a stream member of the Clinical Data Acquisition Standards Harmonization (CDASH) committee and has worked with industry metrics consortiums such as the Metrics Champion Consortium (MCC).
Jeremy Langohr is the Director of Information Technology at Robarts Clinical Trials and is responsible for leading and overseeing our IT infrastructure and software development team, operations and strategy.
Jeremy began his career in IT in 2002 and has held several positions in not-for-profit and public and private life sciences environments supporting hundreds of users around the world. This experience was essential for Jeremy as he successfully lead several large, complex infrastructure migrations including the 2016 Robarts Clinical Trials head office and datacenter relocation. Jeremy is passionate about user-centric IT and Information Security and holds Certified Information Systems Security Professional (CISSP) and IT Service Management (ITIL) certifications. A graduate of the University of Western Ontario, Jeremy is a strong communicator who believes the key to effective IT is putting people first.
Christine Mueller-Rosenau, Director Clinical Study Management has over 20 years’ experience monitoring and managing global, full service clinical studies in a CRO environment.
Christine started her career in clinical research in 1995 as a CRA monitoring sites in Germany, Belgium and the UK. She became a Project Manager in 2000 and has worked as a Project Director since 2006. Christine joined Robarts in April 2013. Over the last 16 years she has managed studies in a variety of disease indications (with a strong focus on IBD) in Western, Central and Eastern Europe, North and South America, Asia and Africa. In her role as a Director Clinical Study Management Christine provides leadership and oversight to support Robarts full service studies. As a member of the senior leadership team she takes part in the development and implementation of organizational strategies and initiatives that ensure superior customer service.
Christine holds a masters degree in Biology and English as well as a Project Management Professional (PMP) ® certification.
Mike Nicell is the Director, Business Development at Robarts Clinical Trials and in this capacity functions to develop new, and enhance existing client relationships.
Mike has spent his career employed in the medical device and pharmaceutical industry. He has worked for both pharmaceutical and clinical service delivery companies. With experience in the CRO industry, Mike has a strong understanding of all aspects of the clinical trial process. His past experience allows him to effectively listen to client needs, understand the clinical trial at hand and develop proposals that are accurate, clear and transparent.
Prior to his current role, Mike was an outsourcing consultant, Senior Director of Business Development at PharmaNet, Director of Business Operations at Danapharm Clinical Research and in various commercial roles at AstraZeneca. Mike holds a Bachelor’s Degree in Science as well as an Honors Bachelor Degree of Commerce.
Daniel Philpott has over 15 years of experience working within the biopharmaceutical environment in both Pharmaceutical and CRO settings.
Daniel started his career working in a Phase one unit in London, UK in 2001 in a quality and inhouse monitoring role. Daniel became a CRA in 2005 and monitored sites across North America for various organizations before becoming a CRA manager in 2012. Prior to joining Robarts in 2017 Daniel was a Senior Manager with PAREXEL overseeing the clinical operations business process lead group, responsible for all clinical related metrics, processes and system implementation globally for a major client partnership. In his role as Director Monitoring and Site Management he is responsible for providing leadership and oversight to support the Global Monitoring and Site group. As part of the senior leadership team he participates in the development and implementation of organizational strategies, technologies and best practices that ensure superior customer service, staff development, quality information management reporting.
Daniel holds a Bachelor’s degree in Biochemistry, a Certification in Clinical Research and a Masters Of Business specializing in the Management of Technology and Innovation. Daniel Is also a member of the Royal Society of Biology.
Karen is currently Director, Quality Assurance at Robarts Clinical Trials. She works with operational groups to maximize efficiency and productivity in both clinical research activities as well as system validation.
Karen earned Honors of her Bachelor of Science Degree, in biology and pharmacology from McMaster University in 1996. Drawing on her years of pharmaceutical industry experience, Ms. Toulouse has lead the team at Robarts Clinical Trials in the implementation of quality processes since 2005. Her expertise in ICH-GCP, computer system validation and global regulations are instrumental in her leadership to further the quality goals of the organization.
Her work experience includes internal and external audits, including vendor assessments of clinical laboratories, manufacturing sites and other service providers. She is a member of the Society of Quality Assurance (GCP Certified since 2009).
Courtney Sweet is the Director, Imaging Project Operations at Robarts Clinical Trials and is responsible for providing leadership and oversight of the global activities and timelines related to imaging projects.
Courtney has 18 years of experience in the clinical research field spanning over a number of clinical operations positions in pharmaceutical and CRO companies. Courtney started her career in 1999 as a Clinical Trial Associate for a biotechnology company. She then spent 5 years as a CRA at Pfizer, monitoring Phase I – III studies across multiple therapeutic areas in North America.
Prior to joining Robarts, Courtney was a Clinical Study Manager and Associate Director of project management at Quintiles, overseeing project delivery for large global trials in oncology and rheumatoid arthritis. Courtney joined Robarts in 2013 as a Project Director. Over the past 4 years she has lead full service trials as well as imaging studies involving endoscopy, histopathology and MRE. Courtney holds a Bachelor’s Degree in Biology and Psychology.
The leadership team at Robarts is grateful to benefit from the collective wisdom and experience of a strong and diverse Board of Directors. Their knowledge and high standards support us as we manage the business with a view to maximizing research gains and capabilities and stakeholder value. This is done via an appropriate system of corporate governance and internal controls, always ensuring our conduct is ethical, legal and visionary. They have been an integral part of our growth.
Paul Knill has been the board chair for Robarts Clinical Trails Inc. since 2014.
Paul served as Managing Partner at the Canadian Law Firm, Siskinds LLP, during a period of significant expansion and change. His leadership encouraged innovative gathering and sharing of intellectual capital among business unit members. Paul went on to serve as an adjunct professor at Western University law school, and he currently contributes his corporate governance expertise by serving on the boards of a diverse number of Corporations.
Paul earned his law degree from Western University, and is a graduate of the Institute of Corporate Directors, Rotman School of Management.
Richard Campbell received professional accreditation as a Certified General Accountant in July, 1984. He joined the Financial Services Department of Western University in June 1987 and is currently the Director of Business Planning and Strategic Project Management.
In this role, Rick is responsible for financial oversight of over thirty diverse ancillary operations, academic support units, research core facilities, and associated companies at Western University. Rick has been actively involved in engaging students in local and international community service learning projects and was honored by the Governor General of Canada with the Golden Jubilee Medal in 2002 for exemplary contributions to the community.
As Vice President (Research), John oversees the research enterprise and mission at one of Canada’s leading research-intensive universities, providing leadership for Research Development & Services, Human Research Ethics, Animal Care & Veterinary Services, Western Research Parks and WORLDiscoveries.
John earned his undergraduate degree at the University of Western Ontario in 1978 and his PhD in Biochemistry at McMaster University in 1983. He was a Medical Research Council of Canada Fellow and MRC Centennial Fellow at the Massachusetts Institute of Technology from 1983-86 prior to returning to McMaster as an Assistant Professor and Senior Scientist of the National Cancer Institute of Canada in the Department of Biochemistry and Biomedical Sciences. During his time at McMaster John held progressively senior administrative positions including Chair of the Department of Biochemistry and Biomedical Science, Associate Dean of Research in the Faculty of Health Sciences, and two terms as Dean of the Faculty of Science prior to coming to Western University.
John’s primary research interests focus on molecular studies of gene control and protein function in metabolic regulation and hormone action as related to viral infections and such diseases as cancer. His research has been generously funded through operating grants from the MRC, Canadian Institutes of Health Research, the Heart and Stroke Foundation of Ontario, and the National Cancer Institute of Canada among other private and public sector agencies. He has published extensively in top peer-reviewed journals and has contributed to an array of national and international research organizations through scholarly and professional activities.
In his role at Western, John is leading the efforts to become a more globally preeminent, research-intensive university by enhancing research excellence, impact and capacity, raising the stature nationally and internationally, expanding the number of areas that achieve excellence on the world stage. In this role, John continues to implement strategies and programs to enhance research excellence and scholarship across the full spectrum of disciplines at Western and its affiliated Institutions, in attracting, retaining and mentoring established and future research leaders, and in advancing interdisciplinary research strategies and partnerships to benefit the social, health, economic and cultural well-being of citizens in Canada and across the globe.
Dr. Ross Feldman is Medical Director, Cardiac Sciences Program for the Winnipeg Regional Health Authority, in addition he is also Professor of Medicine at the University of Manitoba.
He was just recently the Chair of Medicine at Memorial University of Newfoundland, St. John’s Newfoundland & Labrador, Canada. He is the author of more than 200 original manuscripts, reviews and book chapters. His clinical research program centers on the development of new approaches to the management of hypertension and specifically the development of innovative strategies to improve blood pressure control.
A major focus of his efforts has been in the prevention and control of hypertension in Canada and specifically in the knowledge translation of optimal treatment approaches for hypertension management. Among past leadership positions, Dr. Feldman served as the first Chair of the Steering Committee of the Canadian Hypertension Education Program, the organization that since 1999 has produced, disseminated and implemented annually updated guidelines for management of hypertension. As well, he served as President of the Canadian Hypertension Society. He was also the founding President of Hypertension Canada- leading the process of integrating the efforts of the Canadian Hypertension Society, Canadian Hypertension Education Program and Blood Pressure Canada.
He has received a number of awards and scholarships in recognition of his contributions in research, teaching and for his efforts in the prevention and control of hypertension in Canada. These include the George Morris Piersol Research and Teaching Scholarship from the American College of Physicians, a Career Investigator Award from the Heart and Stroke Foundation of Ontario, the Burroughs-Wellcome Clinical Pharmacology Award and the Senior Investigator Award from the Canadian Society for Clinical Pharmacology as well as the Distinguished Service/Research Award of the Canadian Hypertension Society. He also the recipient of the George Fodor Award from Hypertension Canada for outstanding contributions to the prevention and control of hypertension.
Dr. Mills co-founded BioStorage Technologies Inc. (BST) in 2002, recognizing the need for the biopharmaceutical industry to store and manage samples for future biomarker and target identification as well as for analyses performed to meet regulatory requirements. He grew BST through angel and series A funding to a global company that was acquired by Brooks Automation in December 2015.
Since that time, he has been Chairman of DGP Intelsius Ltd., a UK headquartered company specializing in global cold chain packaging solutions. He also serves on the boards of hc1.com, a pioneer in healthcare relationship management and Diversigen Inc., an early stage Company at Baylor College of Medicine. He has also been a director of IBT Labs and Chantest, both of which were acquired in successful transactions. Before founding BST, Dr. Mills served for four years as corporate senior vice president and president of clinical support services for Covance, Inc., a leading contract research organization headquartered in Princeton, New Jersey. While there, he was responsible for a clinical services division that employed more than 2,000 staff globally. From 1991 to 1998 he was corporate vice president and president of Covance’s clinical business in Europe, operating in 14 countries.
Prior to 1991, Dr. Mills held senior positions for Johnson and Johnson’s pharmaceutical division in Asia (based in Singapore) and the U.K. From 1976 to 1982 he served in the Royal Air Force as a specialist in Aviation Medicine at Farnborough, UK. Dr. Mills received his MD from Cambridge University and his PhD in endocrinology from Surrey University in the United Kingdom. He holds diplomas in pharmaceutical medicine, aviation medicine and marketing and has authored more than 40 scientific papers as well as a textbook on aviation medicine.
Dr. Strong graduated from Queens University in Kingston in 1982. This was followed by Neurology training at Western University from 1982 to 1987, and post graduate training at the Laboratory of Central Nervous System Studies at the National Institutes of Health, Bethesda, Maryland from 1987 to 1990.
He served as Director, Motor Neuron Diseases Clinic, London Health Sciences Centre from 1990 to 2010 and Chief of Neurology and Co-chair, Department of Clinical Neurological Sciences from 2000 to 2010. Dr. Strong has edited or co-edited three textbooks on Amyotrophic lateral sclerosis (ALS), published more than 145 peer-reviewed articles and 28 chapters, and given more than 120 invited lectures related to his research in ALS.
Dr. Strong was awarded the Sheila Essey Award in 2005 and the Forbes Norris Award in 2008, and is the only Canadian to have received both international awards for ALS research. He was elected as a fellow of the American Academy of Neurology in 2008 and a Fellow of the Canadian Academy of Health Sciences in 2009. In 2012, he received the Queen Elizabeth II Golden Jubilee medal for his work in ALS research and teaching.
Dr. van Deventer was trained as an internist and board certified gastroenterologist, received a doctorate of philosophy from the University of Amsterdam, worked as a scientist at Rockefeller University and became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam in 1995.
In 1998 he co-founded Amsterdam Molecular Therapeutics (AMT; currently Uniqure), a gene therapy company that develops AAV-based gene therapy products. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Dr. van Deventer has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world (Glybera). He currently is a Managing Partner at Forbion Capital Partners and Professor of Translational Gastroenterology Leiden University Medical Center. He is a member of the Boards of Argos Therapeutics (Durham, USA), Uniqure (Amsterdam, The Netherlands), Hookipa (Vienna, Austria), Staten Biotechnology (Naarden, The Netherlands) and enGene (Montreal, Canada).